Clinical Images: B cell depletion in the appendix following rituximab treatment

Arthritis and Rheumatism

Volumn 54, Issue 7, 2006, Pages 2151-

  Paran, Daphna ^a   Trej'o, Leonor ^a   Caspi, Dan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; COMPLEMENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DNA ANTIBODY; IMMUNOGLOBULIN; PREDNISONE; RITUXIMAB;

ACUTE APPENDICITIS; ADULT; APPENDIX; ARTICLE; B LYMPHOCYTE; CASE REPORT; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, MONOCLONAL; APPENDECTOMY; APPENDICITIS; APPENDIX; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; THROMBOCYTOPENIA;

EID: 33745911945     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21871     Document Type: Article

References (6)

1. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkins lymphoma and chronic lymphocytic leukemia. Drugs 2003;63:803-43.
2. Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005;78:275-80.
3. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy [review]. Arthritis Rheum 2003;48:1484-92.
4. Silverman GJ. Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic [editorial]. Arthritis Rheum 2005;52:371-7.
5. Schroder C, Azimzadeh AM, Wu G, Price JO, Atkinson JB, Pierson RN. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol 2003;12:19-28.
6. Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 2002;206:519-27.